You are here

Shawn Nelson, Jr.


Melillo B, Zoller J, Hua BK, Verho O, Borghs J, Nelson SD Jr, et al. Synergistic effects of stereochemistry and appendages on the performance diversity of a collection of synthetic compounds. J Am Chem Soc. 2018;140(37):11784–11790. 

Nelson SD Jr, Wawer MJ, Schreiber SL. Divergent synthesis and real-time biological annotation of optically active tetrahydrocyclopenta[c]pyranone derivatives. Org Lett. 2016;18(24):6280–6283. 

Shawn Nelson, Jr., Ph.D.

Shawn Nelson, Jr. is a research scientist I working within the medicinal chemistry team in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, under the direction of Michel Weïwer. He is concurrently a member of the Stanley Center for Psychiatric Research team, wherein he focuses on developing novel small molecules toward treating severe psychiatric diseases such as schizophrenia. Within these projects, Nelson applies principles of rational drug design to develop small molecules targeting G-protein coupled receptors and ligand-gated ion channels.

Nelson joined the Broad Institute in November 2013 as a graduate student in the Schrieber lab. After finishing his A.M./Ph.D. in chemistry at Harvard University in November 2018, he worked for a year at a small pharmaceutical company in the San Francisco Bay area, before returning to the Broad in October 2019. He also holds a B.S. in chemistry from Rensselaer Polytechnic Institute. 

Contact Shawn Nelson, Jr. via email at

January 2021